HAE
Haemonetics Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+41/100
Last price
103.52
▼ 1.16 (1.11%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
104.19
Prev close
104.68
Day high
105.58
Day low
102.81
Volume
542.04K
Market cap
$4.71B
P/E (TTM)
50.01
52W range
48.17 – 110.45
Day trading desk
Gap from prior close
-0.47%
Prior close 104.68
VWAP
103.52
-0.00% from price
Relative volume
1.10×
Normal
Session range
2.70%
102.80 – 105.58
Position in range
26%
Near session low
ATR (14D)
2.47
2.38% of price
Prior day high
106.26
PDH
Prior day low
103.65
PDL
Bid / ask spread
—
Quote not published
Session volume
747.39K
Avg 678.83K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.16%
-4.1%
1M
+0.58%
-0.6%
3M
+40.23%
+35.7%
6M
+73.81%
+55.6%
YTD
+29.16%
+14.9%
1Y
+105.03%
+88.6%
3Y
+15.56%
-66.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
17 more panels on HAE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
574.63K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 24, 26 | KROLL MARK W Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | ABERNATHY ROBERT E Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | COYLE MICHAEL J Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | ZANE ELLEN M Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | MADAUS MARTIN D PH.D. Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | POMEROY CLAIRE Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | BRYANT DIANE M Director |
STOCK | 2.54K | $0 | Direct |
| Jul 24, 26 | JOHNSON LLOYD EMERSON Director |
STOCK | 2.54K | $0 | Direct |
| May 15, 26 | DARECCA JAMES Chief Financial Officer |
STOCK | 29.31K | $0 | Direct |
| May 15, 26 | MILLER LAURIE A Officer |
STOCK | 13.32K | $0 | Direct |
| May 15, 26 | GALVIN ROY Officer |
STOCK | 27.54K | $0 | Direct |
| May 15, 26 | MAUNSELL FARRIS MARYANNE Officer |
STOCK | 2.22K | $0 | Direct |
| May 15, 26 | SIMON CHRISTOPHER Chief Executive Officer |
STOCK | 78.34K | $0 | Direct |
| May 15, 26 | BASIL MICHELLE L General Counsel |
STOCK | 28.42K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABERNATHY ROBERT E |
Director | 27.52K | Stock Award(Grant) |
BASIL MICHELLE L |
General Counsel | 68.83K | Stock Award(Grant) |
DARECCA JAMES |
Chief Financial Officer | 54.44K | Stock Award(Grant) |
DOCKENDORFF CHARLES J |
Director | 25.04K | Stock Award(Grant) |
GALVIN ROY |
Officer | 39.88K | Stock Award(Grant) |
KROLL MARK W |
Director | 27.30K | Stock Award(Grant) |
MILLER LAURIE A |
Officer | 41.30K | Stock Award(Grant) |
POMEROY CLAIRE |
Director | 19.41K | Stock Award(Grant) |
SIMON CHRISTOPHER |
Chief Executive Officer | 444.70K | Stock Award(Grant) |
ZANE ELLEN M |
Director | 21.91K | Stock Award(Grant) |
Fundamentals
Market cap$4.71B
Enterprise value$5.66B
Revenue (TTM)$1.35B
Gross profit$802.16M
EBITDA$358.79M
Net income$96.29M
EPS (TTM)$2.07
Free cash flow$312.84M
Total cash$224.52M
Total debt$1.17B
Book value / share$18.41
Shares outstanding45.50M
Float44.89M
Short % of float8.81%
Dividend yield0.00%
Beta (5Y)0.61
Valuation & profitability ratios
Trailing P/E50.01
Forward P/E17.92
PEG ratio1.66
Price / sales—
Price / book5.62
EV / revenue4.19
EV / EBITDA15.77
Gross margin59.33%
Operating margin17.93%
Profit margin7.12%
Return on equity11.20%
Return on assets6.60%
Debt / equity140.27
Current ratio3.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.33B | $1.36B | $1.31B | $1.17B | -2.0% |
| Operating revenue | $1.33B | $1.36B | $1.31B | $1.17B | -2.0% |
| Cost of revenue | $546.44M | $611.87M | $617.51M | $553.56M | -10.7% |
| Gross profit | $787.59M | $748.96M | $691.55M | $615.10M | +5.2% |
| Research & development | $59.77M | $62.72M | $54.44M | $50.13M | -4.7% |
| Selling, general & admin | $442.42M | $436.79M | $429.78M | $376.68M | +1.3% |
| Total operating expense | $546.18M | $547.77M | $516.25M | $459.45M | -0.3% |
| Operating income | $241.40M | $201.19M | $175.30M | $155.65M | +20.0% |
| Net interest income | -$28.70M | -$9.75M | -$13.02M | -$14.63M | -194.5% |
| Pre-tax income | $128.03M | $212.07M | $151.87M | $141.40M | -39.6% |
| Tax provision | $30.72M | $44.39M | $34.31M | $26.00M | -30.8% |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | -42.0% |
| Net income to common | $97.31M | $167.68M | $117.56M | $115.40M | -42.0% |
| Basic EPS | 2.06 | 3.33 | 2.32 | 2.27 | -38.1% |
| Diluted EPS | 2.05 | 3.31 | 2.29 | 2.24 | -38.1% |
| EBIT | $156.73M | $221.82M | $164.88M | $156.03M | -29.3% |
| EBITDA | $268.45M | $337.40M | $262.10M | $249.34M | -20.4% |
| Basic shares | 47.18M | 50.33M | 50.71M | 50.78M | -6.3% |
| Diluted shares | 47.35M | 50.73M | 51.40M | 51.42M | -6.7% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $245.44M | $306.76M | $178.80M | $284.47M | -20.0% |
| Cash & short-term investments | $245.44M | $306.76M | $178.80M | $284.47M | -20.0% |
| Accounts receivable | $216.85M | $202.66M | $206.56M | $179.14M | +7.0% |
| Inventory | $306.37M | $365.14M | $317.20M | $259.38M | -16.1% |
| Total current assets | $834.88M | $934.98M | $768.90M | $769.72M | -10.7% |
| Property, plant & equipment | $305.76M | $284.05M | $311.36M | $310.88M | +7.6% |
| Goodwill & intangibles | $1.10B | $1.06B | $971.20M | $742.00M | +4.2% |
| Total assets | $2.40B | $2.45B | $2.20B | $1.93B | -2.2% |
| Total current liabilities | $282.60M | $578.11M | $300.38M | $251.82M | -51.1% |
| Current debt | $5.01M | $303.56M | $10.23M | $11.78M | -98.3% |
| Long-term debt | $1.22B | $921.23M | $797.56M | $754.10M | +32.4% |
| Total debt | $1.22B | $1.22B | $807.79M | $765.89M | -0.0% |
| Total liabilities | $1.60B | $1.63B | $1.24B | $1.12B | -1.9% |
| Retained earnings | $279.34M | $352.17M | $360.46M | $253.17M | -20.7% |
| Shareholder equity | $796.32M | $820.84M | $959.96M | $818.00M | -3.0% |
| Working capital | $552.28M | $356.86M | $468.52M | $517.91M | +54.8% |
| Net tangible assets | -$307.70M | -$239.18M | -$11.24M | $76.00M | -28.7% |
| Shares issued | 45.25M | 48.22M | 50.79M | 50.45M | -6.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | -42.0% |
| Depreciation & amortisation | $111.72M | $115.59M | $97.22M | $93.31M | -3.3% |
| Stock-based compensation | $33.83M | $29.64M | $28.33M | $25.58M | +14.1% |
| Change in working capital | -$12.93M | -$91.98M | -$63.07M | $25.50M | +85.9% |
| Operating cash flow | $293.22M | $181.72M | $181.75M | $273.06M | +61.4% |
| Capital expenditure | -$32.78M | -$39.28M | -$38.13M | -$191.33M | +16.5% |
| Investing cash flow | -$179.55M | -$161.90M | -$322.39M | -$143.79M | -10.9% |
| Share buybacks | -$175.00M | -$225.00M | $0 | -$75.00M | +22.2% |
| Financing cash flow | -$178.46M | $108.82M | $38.16M | -$100.36M | -264.0% |
| Free cash flow | $260.44M | $142.45M | $143.63M | $81.73M | +82.8% |
| End cash position | $245.44M | $306.76M | $178.80M | $284.47M | -20.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $339.38M | $346.35M | $338.97M | $327.31M | $321.39M | -2.0% |
| Operating revenue | $339.38M | $346.35M | $338.97M | $327.31M | $321.39M | -2.0% |
| Cost of revenue | $136.58M | $148.14M | $136.58M | $132.57M | $129.15M | -7.8% |
| Gross profit | $202.80M | $198.21M | $202.39M | $194.74M | $192.24M | +2.3% |
| Research & development | $16.20M | $14.45M | $14.19M | $14.87M | $16.26M | +12.1% |
| Selling, general & admin | $118.94M | $120.93M | $109.15M | $101.61M | $110.72M | -1.6% |
| Total operating expense | $145.34M | $145.87M | $134.27M | $127.67M | $138.37M | -0.4% |
| Operating income | $57.46M | $52.34M | $68.11M | $67.08M | $53.87M | +9.8% |
| Net interest income | -$9.88M | -$5.37M | -$7.42M | -$7.21M | -$8.70M | -83.9% |
| Pre-tax income | $47.57M | -$28.40M | $59.98M | $51.28M | $45.17M | +267.5% |
| Tax provision | $14.56M | -$8.25M | $15.23M | $12.60M | $11.14M | +276.5% |
| Net income | $33.01M | -$20.15M | $44.74M | $38.68M | $34.03M | +263.8% |
| Net income to common | $33.01M | -$20.15M | $44.74M | $38.68M | $34.03M | +263.8% |
| Basic EPS | 0.73 | -0.44 | 0.96 | 0.81 | 0.71 | +267.0% |
| Diluted EPS | 0.72 | -0.44 | 0.95 | 0.81 | 0.70 | +263.6% |
| EBIT | $57.46M | -$23.02M | $67.40M | $58.49M | $53.87M | +349.5% |
| EBITDA | $84.57M | $4.29M | $94.78M | $86.75M | $82.63M | +1,869.5% |
| Basic shares | 45.36M | 46.22M | 46.79M | 47.59M | 48.11M | -1.9% |
| Diluted shares | 45.70M | 46.22M | 46.99M | 47.66M | 48.35M | -1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $223.38M | $245.44M | $363.37M | $296.43M | $292.90M | -9.0% |
| Cash & short-term investments | $223.38M | $245.44M | $363.37M | $296.43M | $292.90M | -9.0% |
| Accounts receivable | $216.07M | $216.85M | $195.71M | $207.07M | $200.75M | -0.4% |
| Inventory | $306.74M | $306.37M | $321.19M | $336.21M | $360.53M | +0.1% |
| Total current assets | $810.83M | $834.88M | $943.67M | $899.68M | $913.16M | -2.9% |
| Property, plant & equipment | $303.78M | $305.76M | $297.23M | $292.48M | $286.87M | -0.6% |
| Goodwill & intangibles | $1.09B | $1.10B | $1.03B | $1.03B | $1.06B | -1.1% |
| Total assets | $2.37B | $2.40B | $2.49B | $2.44B | $2.46B | -1.3% |
| Total current liabilities | $263.24M | $282.60M | $539.87M | $548.32M | $531.41M | -6.9% |
| Current debt | $4.96M | $5.01M | $304.75M | $304.33M | $303.95M | -1.2% |
| Long-term debt | $1.17B | $1.22B | $919.99M | $920.39M | $920.83M | -4.1% |
| Total debt | $1.17B | $1.22B | $1.22B | $1.22B | $1.22B | -4.1% |
| Total liabilities | $1.53B | $1.60B | $1.58B | $1.59B | $1.58B | -4.5% |
| Retained earnings | $311.52M | $279.34M | $381.09M | $336.32M | $356.05M | +11.5% |
| Shareholder equity | $837.10M | $796.32M | $911.45M | $849.17M | $882.30M | +5.1% |
| Working capital | $547.60M | $552.28M | $403.81M | $351.36M | $381.75M | -0.8% |
| Net tangible assets | -$254.29M | -$307.70M | -$115.11M | -$185.28M | -$175.63M | +17.4% |
| Shares issued | 45.47M | 45.25M | 46.83M | 46.75M | 48.16M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $33.01M | -$20.15M | $44.74M | $38.68M | $34.03M | — | +263.8% |
| Depreciation & amortisation | $27.11M | $27.32M | $27.39M | $28.25M | $28.76M | — | -0.8% |
| Stock-based compensation | $9.31M | $9.13M | $7.80M | $7.59M | $9.31M | — | +2.0% |
| Change in working capital | -$20.00M | $4.66M | $11.81M | $26.09M | -$55.48M | — | -529.5% |
| Operating cash flow | $52.32M | $70.94M | $93.56M | $111.32M | $17.39M | — | -26.2% |
| Capital expenditure | -$7.91M | -$17.66M | -$6.35M | -$5.02M | -$3.75M | — | +55.2% |
| Investing cash flow | -$22.23M | -$86.61M | -$29.47M | -$30.47M | -$33.00M | — | +74.3% |
| Share buybacks | — | -$100.00M | $0 | — | — | -$150.00M | — |
| Financing cash flow | -$51.53M | -$101.50M | $2.03M | -$76.55M | -$2.44M | — | +49.2% |
| Free cash flow | $44.42M | $53.28M | $87.22M | $106.31M | $13.64M | — | -16.6% |
| End cash position | $223.38M | $245.44M | $363.37M | $296.43M | $292.90M | — | -9.0% |
Options analytics
Put / call volume
0.15
Call-heavy session
Put / call open interest
1.04
Positioning, not flow
Max pain
100.00
-3.4% from spot
ATM implied vol
63.9%
Nearest strike to spot
Skew (10% OTM)
+9.9%
Puts bid over calls
Call volume
119
Contracts, this expiry
Put volume
18
Contracts, this expiry
Heaviest call OI
100.00
50 contracts
Heaviest put OI
90.00
50 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.08 | 1.14 | +5.9% |
| Mar 2026 | 1.27 | 1.29 | +1.4% |
| Dec 2025 | 1.25 | 1.31 | +4.8% |
| Sep 2025 | 1.11 | 1.27 | +14.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.29 | 11 | $345.15M | +5.5% |
| Next quarter | 1.36 | 11 | $357.56M | +5.5% |
| Current year | 5.31 | 11 | $1.42B | +6.2% |
| Next year | 5.78 | 11 | $1.50B | +5.5% |
Analyst targets & ownership
Mean target$111.50
High target$125.00
Low target$86.00
Implied upside7.71%
Analyst count10
ConsensusBUY
Strong buy / Buy4 / 5
Hold2
Sell / Strong sell0 / 0
Held by insiders1.26%
Held by institutions112.44%
Institutions holding465
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
105.23
-1.62% from price
SMA 20
105.56
-1.93% from price
SMA 50
99.87
+3.65% from price
SMA 100
86.09
+20.25% from price
SMA 200
75.26
+37.55% from price
EMA 12
105.08
-1.49% from price
EMA 26
103.89
-0.36% from price
EMA 50
98.95
+4.62% from price
RSI (14)
49.1
Neutral
MACD (12,26,9)
1.19
Hist -0.86
ATR (14)
2.47
2.38% of price
Realised vol 30D
17.2%
Annualised
Bollinger upper
109.45
20, 2σ
Bollinger lower
101.66
20, 2σ
50 / 200 cross
Golden
99.87 vs 75.26
Trend bias
Above 200
+37.55%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.08
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
17.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-40.1%
Peak to trough
Max drawdown 5Y
-51.0%
Peak to trough
ATR 14
2.47
2.38% of price
Beta (reported)
0.61
5Y monthly, from filing
Short interest
Shares short
3.42M
Prior 2.76M
Change vs prior
+24.0%
Shorts adding
% of float
8.81%
Normal
% of shares out
7.53%
Against total outstanding
Days to cover
4.7
Liquid
Float
44.89M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 26 | Citigroup | UPGRADE | Neutral | Buy |
| Sep 3, 26 | Raymond James | MAINTAINED | Outperform | Outperform |
| Aug 21, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Aug 19, 26 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Aug 18, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Aug 7, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Aug 6, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 15, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jun 26, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 17, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 15, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateDec 3, 2012
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-18
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-28
Annual Report to Shareholders
ARS · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-05
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-28
Periodic Financial Reports
10-K · 2026-05-20
Corporate Changes & Voting Matters
8-K · 2026-05-07
Headlines
PAHC vs. HAE: Which Stock Is the Better Value Option?
Zacks · 2d ago
3 Small-Cap Stocks with Questionable Fundamentals
StockStory · 6d ago
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
PR Newswire · 6d ago
Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus
Simply Wall St. · 14d ago
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Zacks · 16d ago
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Zacks · 18d ago
Haemonetics Shares Rise After Citigroup Upgrade
MT Newswires · 19d ago
HAE, TWST Stocks Jump To Over 5-Year Highs – What’s Driving The Gains Today?
Stocktwits · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.